Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the en...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Bukkems, Vera, Necsoi, Coca, Tenorio, Carmen Hidalgo, Garcia, Coral, Rockstroh, Jürgen, Schwarze-Zander, Caroline, Lambert, John S, Burger, David, Konopnicki, Deborah, Colbers, Angela
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Online Only Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744974/
https://ncbi.nlm.nih.gov/pubmed/32330231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados